公开(公告)号：US20240360222A1

公开(公告)日：2024-10-31

申请号：US18662493

申请日：2024-05-13

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC: C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09

CPC classification number: C07K16/2839 ,  A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20220064287A1

公开(公告)日：2022-03-03

申请号：US17527681

申请日：2021-11-16

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH

IPC: C07K16/28 ,  C07K16/30 ,  C07K19/00 ,  A61P35/00 ,  C12N15/62

Abstract: Provided is an antibody effective in treating tumors and the like. The antibody recognizes an epitope that contains an N-glycosylation site of human CD98hc and that is exposed by inhibiting N-linked glycosylation.

公开(公告)号：US20200283533A1

公开(公告)日：2020-09-10

申请号：US16808451

申请日：2020-03-04

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC: C07K16/28 ,  A61K35/17 ,  C12N5/10 ,  C12N15/09 ,  A61K39/00 ,  C07K19/00 ,  A61P35/00

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20180230216A1

公开(公告)日：2018-08-16

申请号：US15751574

申请日：2016-08-02

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC: C07K16/28 ,  A61K35/17 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N15/09 ,  C12N5/10

CPC classification number: C07K16/2839 ,  A61K35/17 ,  A61K39/0011 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33 ,  C12N5/10 ,  C12N15/09

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20180230212A1

公开(公告)日：2018-08-16

申请号：US15751717

申请日：2016-08-09

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/62 ,  C07K19/00

CPC classification number: C07K16/28 ,  A61K38/1709 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2896 ,  C07K16/3061 ,  C07K19/00 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/62

Abstract: Provided is an antibody effective in the treatment of tumors and the like. An antibody that includes an N-type glycosylation site of human CD98hc and recognizes an epitope exposed by inhibition of N-type glycosylation modification.